Merck Frosst
Patients and Caregivers

Rotavirus

Is RotaTeq® effective?

RotaTeq® has demonstrated 98% efficacy against severe rotavirus infections, and 74% efficacy against rotavirus infection of any severity, through the first rotavirus season.3,11,*

It has also been shown to reduce rotavirus-related emergency department visits and hospitalizations by 94%.3,11

As with any vaccine, vaccination with RotaTeq® may not result in complete protection in all recipients.

* Second-season efficacy against severe rotavirus gastroenteritis was 88% and that against any severity was 63%. 11 The efficacy of RotaTeq® beyond the second season post-vaccination was not evaluated.3


This product information is intended only for residents of Canada.

®Registered Trademark of Merck & Co., Inc.  Used under license.

This site is for residents of Canada. / This site was updated on October 26, 2011.